ArticleJournal of clinical tuberculosis and other mycobacterial diseases2020
Phase III, placebo-controlled, randomized, double-blind trial of tableted, therapeutic TB vaccine (V7) containing heat-killed
Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- Immunotherapy for tuberculosis: current strategies and future directions.Military Medical Research · 2025Review
- Optimizing antigen selection for the development of tuberculosis vaccines.Cell insight · 2024Review
- Tuberculosis vaccine developments and efficient delivery systems: A comprehensive appraisal.Heliyon · 2024Review
- Key advances in vaccine development for tuberculosis-success and challenges.NPJ vaccines · 2023Review
- Vaccines against Tuberculosis: Where Are We Now?Vaccines · 2023Review
- Immunization with a heat-killed preparation of Mycobacterium vaccae NCTC 11659 enhances auditory-cued fear extinction in a stress-dependent manner.Brain, behavior, and immunity · 2023Article
- Rapidly GrowingInternational journal of molecular sciences · 2021Review
- A review of the BCG vaccine and other approaches toward tuberculosis eradication.Human vaccines & immunotherapeutics · 2021Review
- Comparing the effects of two different strains of mycobacteria, Mycobacterium vaccae NCTC 11659 and M. vaccae ATCC 15483, on stress-resilient behaviors and lipid-immune signaling in rats.Brain, behavior, and immunity · 2021Article
- COVID-19 vaccine development: What lessons can we learn from TB?Annals of clinical microbiology and antimicrobials · 2020Review
- Review
- Integrating fish models in tuberculosis vaccine development.Disease models & mechanisms · 2020Review
- Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis.Seminars in immunology · 2020Review
- Biovacc-19: A Candidate Vaccine for Covid-19 (SARS-CoV-2) Developed from Analysis of its General Method of Action for Infectivity.QRB discovery · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 14 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveImmunotherapy of tuberculosis (TB) to shorten treatment duration represents an unmet medical need. Orally delivered, tableted TB vaccine (V7) containing heat-killed
methodsThe outcome of Phase III trial of V7 containing 10 µg of hydrolyzed
resultsAfter one month mycobacterial clearance was observed in 68% (
conclusionOral
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.